content_top
43 companies, 1 interpreter! Insight, foresight
and recommendation 

Athersys, Inc. (ATHX)

1.94
0.08
(4.30%)
Sep 11, 4:00PM EDT
content_middle

Athersys, Inc, a biotechnology company, focuses on the research and development in the field of regenerative medicine.

Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.

ATHX's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which has completed Phase 2 study for treating patients suffering from moderate and severe ischemic stroke; that is in Phase 2 clinical study for treating patients with acute myocardial infarction; and, which is in Phase 1/2 clinical study for treating patients with acute respiratory distress syndrome, as well as completed Phase 1 clinical study for patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients; and 5HT2c agonists for the treatment of obesity and other conditions.

Athersys has license and collaboration agreements with Healios K.K. and Chugai Pharmaceuticals Co., Ltd. to develop and commercialize MultiStem cell therapy for ischemic stroke; RTI Surgical, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market; University of Minnesota to develop MultiStem cell therapy platform; and Bristol-Myers Squibb to provide cell lines expressing well validated drug targets for compound screening and development.

Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.

Previous Close: 
2.09
Open: 
2.11
Bid: 
1.95
Ask: 
2.03
1yr Target Price: 
7.75
Day's Range: 
1.89 - 2.11
52wk Range: 
1.29 - 3.09
Volume: 
1362784
Average Daily Volume: 
758703
Market Capitalization: 
268.85M
Trailing Annual Dividend Yield: 
N/A
Shares Outstanding: 
138.58M
content_right

Pages